BioCentury | Jun 1, 2018
Clinical News

AZ not planning regulatory submissions for Fasenra in COPD

...eosinophilic asthma. AZ and its MedImmune LLC unit have rights to the drug from the BioWa Inc....
BioCentury | May 30, 2018
Clinical News

AZ not planning regulatory submissions for Fasenra in COPD

...eosinophilic asthma. AZ and its MedImmune LLC unit have rights to the drug from the BioWa Inc....
BioCentury | May 18, 2018
Clinical News

AZ's Fasenra fails in Phase III COPD study

...eosinophilic asthma. AZ and its MedImmune LLC unit have rights to the drug from the BioWa Inc....
BioCentury | May 11, 2018
Clinical News

AZ's Fasenra fails in Phase III COPD study

...eosinophilic asthma. AZ and its MedImmune LLC unit have rights to the drug from the BioWa Inc....
BioCentury | Nov 19, 2015
Product R&D

A solid move

...2016. Cantargia signed two deals this year. First, it licensed a mammalian cell line from BioWa Inc....
...production system. Next, it signed an agreement with Glycotope GmbH for product development using the BioWa...
BioCentury | Sep 15, 2014
Clinical News

Benralizumab: Phase IIa data

...asthma. AZ has worldwide rights, excluding Japan and certain Asian countries, to benralizumab from Kyowa's BioWa Inc....
BioCentury | Aug 18, 2014
Clinical News

Benralizumab: Phase III started

...asthma. AZ has worldwide rights, excluding Japan and certain Asian countries, to benralizumab from Kyowa’s BioWa Inc....
BioCentury | Aug 18, 2014
Clinical News

Benralizumab: Phase III started

...asthma. AZ has worldwide rights, excluding Japan and certain Asian countries, to benralizumab from Kyowa’s BioWa Inc....
BioCentury | Jun 30, 2014
Clinical News

Benralizumab: Phase IIb data

...year. AstraZeneca has worldwide rights, excluding Japan and certain Asian countries, to benralizumab from Kyowa’s BioWa Inc....
BioCentury | Mar 24, 2014
Company News

arGEN-X B.V., Lonza, Kyowa Hakko Kirin deal

...arGEN-X received non-exclusive rights from Lonza and Kyowa's BioWa Inc. subsidiary to apply the Potelligent CHOK1SV cell...
...2010 to apply BioWa's Potelligent technology to arGEN-X's mAbs to treat cancer and inflammatory disorders. BioWa...
Items per page:
1 - 10 of 54
BioCentury | Jun 1, 2018
Clinical News

AZ not planning regulatory submissions for Fasenra in COPD

...eosinophilic asthma. AZ and its MedImmune LLC unit have rights to the drug from the BioWa Inc....
BioCentury | May 30, 2018
Clinical News

AZ not planning regulatory submissions for Fasenra in COPD

...eosinophilic asthma. AZ and its MedImmune LLC unit have rights to the drug from the BioWa Inc....
BioCentury | May 18, 2018
Clinical News

AZ's Fasenra fails in Phase III COPD study

...eosinophilic asthma. AZ and its MedImmune LLC unit have rights to the drug from the BioWa Inc....
BioCentury | May 11, 2018
Clinical News

AZ's Fasenra fails in Phase III COPD study

...eosinophilic asthma. AZ and its MedImmune LLC unit have rights to the drug from the BioWa Inc....
BioCentury | Nov 19, 2015
Product R&D

A solid move

...2016. Cantargia signed two deals this year. First, it licensed a mammalian cell line from BioWa Inc....
...production system. Next, it signed an agreement with Glycotope GmbH for product development using the BioWa...
BioCentury | Sep 15, 2014
Clinical News

Benralizumab: Phase IIa data

...asthma. AZ has worldwide rights, excluding Japan and certain Asian countries, to benralizumab from Kyowa's BioWa Inc....
BioCentury | Aug 18, 2014
Clinical News

Benralizumab: Phase III started

...asthma. AZ has worldwide rights, excluding Japan and certain Asian countries, to benralizumab from Kyowa’s BioWa Inc....
BioCentury | Aug 18, 2014
Clinical News

Benralizumab: Phase III started

...asthma. AZ has worldwide rights, excluding Japan and certain Asian countries, to benralizumab from Kyowa’s BioWa Inc....
BioCentury | Jun 30, 2014
Clinical News

Benralizumab: Phase IIb data

...year. AstraZeneca has worldwide rights, excluding Japan and certain Asian countries, to benralizumab from Kyowa’s BioWa Inc....
BioCentury | Mar 24, 2014
Company News

arGEN-X B.V., Lonza, Kyowa Hakko Kirin deal

...arGEN-X received non-exclusive rights from Lonza and Kyowa's BioWa Inc. subsidiary to apply the Potelligent CHOK1SV cell...
...2010 to apply BioWa's Potelligent technology to arGEN-X's mAbs to treat cancer and inflammatory disorders. BioWa...
Items per page:
1 - 10 of 54